Data for EntreMed's ENMD-2076 to Be Presented at the Upcoming AACR-NCI-EORTC Conference
Data from the ENMD-2076 Phase 1 Leukemia Trial to be Included
ROCKVILLE, Md., Nov. 3 /PRNewswire-FirstCall/ -- EntreMed, Inc.
(NASDAQ: ENMD) , a clinical-stage pharmaceutical
company developing therapeutics for the treatment of cancer today
announced presentations for its Aurora A/angiogenic kinase
inhibitor, ENMD-2076, at the AACR-NCI-EORTC International
Conference on Molecular Targets and Cancer Therapeutics to be held
November 15-19, 2009 in Boston, Massachusetts.
ENMD-2076 is an orally-active, Aurora A/angiogenic kinase
inhibitor with a unique kinase selectivity profile and multiple
mechanisms of action. Preclinical studies with ENMD-2076
demonstrate significant antitumor activity, including tumor
regression, in multiple solid and hematological malignancies.
ENMD-2076 has been shown to inhibit a distinct profile of
angiogenic tyrosine kinase targets in addition to Aurora A kinase
and other oncogenic proteins. Aurora kinases are key regulators of
mitosis (cell division), and are often over-expressed in human
cancers. ENMD-2076 targets a defined set of kinases, including
Flt-3 and FGFR3, which have been shown to play important roles in
the pathology of hematological cancers.
EntreMed, Inc. is a clinical-stage pharmaceutical company
committed to developing primarily ENMD-2076, a selective angiogenic
kinase inhibitor, for the treatment of cancer. ENMD-2076 is
currently in Phase 1 studies in advanced cancers, multiple myeloma,
and leukemia. The Company's other therapeutic candidates include
MKC-1, an oral cell-cycle regulator with activity against the mTOR
pathway currently in multiple Phase 2 clinical trials for cancer,
and ENMD-1198, a novel antimitotic agent currently in Phase 1
studies in advanced cancers. The Company also has an approved IND
application for Panzem® in rheumatoid arthritis.
Forward Looking Statements
This release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act with
respect to the outlook for expectations for future financial or
business performance (including the timing of royalty revenues and
future R&D expenditures), strategies, expectations and goals.
Forward-looking statements are subject to numerous assumptions,
risks and uncertainties, which change over time. Forward-looking
statements speak only as of the date they are made, and no duty to
update forward-looking statements is assumed. Actual results could
differ materially from those currently anticipated due to a number
of factors, including those set forth in Securities and Exchange
Commission filings under "Risk Factors," including risks relating
to the need for additional capital and the uncertainty of
additional funding; variations in actual sales of Thalomid®,
risks associated with the Company's product candidates; the
early-stage products under development; results in preclinical
models are not necessarily indicative of clinical results,
uncertainties relating to preclinical and clinical trials; success
in the clinical development of any products; dependence on third
parties; future capital needs; and risks relating to the
commercialization, if any, of the Company's proposed products (such
as marketing, safety, regulatory, patent, product liability,
supply, competition and other risks).
CONTACT: Ginny Dunn Associate Director, Corporate Communications & Investor Relations EntreMed, Inc. 240.864.2643
Posted: November 2009